RespiriTB-1359006 In vitro synergy report for current and new anti-bacterial compounds

Summary

The in vitro synergy report for current and new anti-bacterial compounds will summarize the results of in vitro synergy between antibiotics currently used in standard TB treatment regimens and newly identified anti-bacterial compounds against intracellular (MDR)-Mtb strains in human cells.

More information & hyperlinks

Web resources:

https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5215a5ef4&appId=PPGMS

Associated projects

RespiriTB - Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Organisations

Not specified